Abstract: Behçet's disease is a systemic vasculitis characterized by attacks of acute inflammation, which can affect almost every vascularized area of the body. There is a close correlation between the geographical distribution of HLA-B51 and its prevalence. In the etiopathogenesis there are indications of genetic susceptibility associated with environmental influence. Among the involved genes are those that encompass innate and adaptive immunities. Polymorphisms and epistatic interactions in several genes are described, as well as the presence of imbalance lineage between HLA-B51 and A (MICA). Herpes simplex and Streptococcus sanguinis may be important extrinsic factors. An increase of Th1 response and of IL-21 is observed. The production of IL-21 is positively related to Th17 cells and negatively to T-regs. The mucocutaneous manifestations are Behcet´s disease markers, and their earlier onset indicates a worse prognosis. Recurrent oral ulcers have varied sizes and arrangements, genital ulcers are recurrent, leaving scars, skin lesions are multivaried, and pathergy, although not so frequent, is important for the diagnosis. There are numerous attempts to validate indexes that can evaluate the disease activity and among them the Mucocutaneous Activity Index. This is a specific score that can help with therapeutic decisions and to reduce morbidity, but still lacks validation. The clinical manifestations of other organs are described as well as treatment options.
INTRODUCTION
Behçet's (BD) is a systemic vasculitis of unknown etiology, characterized by recurrent attacks of acute inflammation. The frequency and duration of these outbreaks are unpredictable and do not follow an identifiable pattern from the onset. As a systemic vasculitis, it can affect almost every vascularized area of the body. North Africa or with Asian ancestors than those from European origin, concluding that the risk of BD is not related to the immigrant's age and that the disease has a primarily hereditary basis. In contrast to these studies, two older publications suggested that Turkish immigrants in Germany had a higher prevalence of the disease than natives who did not emigrate, corroborating the environmental influence on its susceptibility. Although the subject remains controversial, the genetic influence is very strong, as it will be shown throughout this article. showed a prevalence of 1/100,000 population among Dutch Caucasians, 71/100,000 among Turks, and 39/100,000 among Moroccans, suggesting that the prevalence among Turks and Moroccans is the same as in their countries of origin. The study did not mention the generation of the affected immigrants. Therefore, more consistent studies with second and third generation patients are needed to evaluate the genetic and environmental importance in the pathogenesis of the disease.
1, [3] [4] [5] [6] It is believed that BD affects more males than females, in a proportion that varies from 1.5-5:1, and is in general more serious in male patients. However, a series of western studies (which included
Brazilian studies) revealed a female predominance, but with less intense manifestations. Factors that modulate this clinical expression are still unknown. 3 In general, BD has a peak age of onset between 20-30 years, and patients who develop the disease from a very young age present with more severe forms, with more organs affected. However, that study did not show the severity or extent of the disease. 6 On the other hand, another paper proposed that men with BD had a risk of involvement of vital organs even if they had only mucocutaneous manifestations at the onset of the disease. 6 These data were confirmed by Italian and Turkish studies. 6 A recent German meta-analysis has confirmed that male sex is more associated with ocular disease, papulo-pustular lesions, superficial and deep vein thromboses, whereas female sex has been associated with genital ulcers and joint involvement. 6 Other meta-analyzes associated the male sex with heart disease and positive pathergy, while erythema nodosum was associated with females. 6 In this way, it seems that gender influences the prognosis, and men have a worse evolution due to the frequency of vital organs affected. 6 The pediatric population is also affected, and a study performed in the UK in 2016 showed that the frequency of having a first-degree relative also affected was 17%. Regarding clinical manifestations, 56.5% of the patients showed gastrointestinal involvement and 28.3%, central nervous system involvement. However, these data were not very well documented by means of complementary examinations. 5 Positive skin pathergy test (SPT) results vary among geographic areas, with high sensitivity and specificity in patients from Turkey, some Mediterranean and Middle East countries, and Japan. 4 However, current studies show a decline in this trend.
4 Some studies have been directed to the research of single nucleotide polymorphisms (SNPs) and others to epistatic interactions with endoplasmic reticulum associated aminopeptidase 1 (ERAP-1).
GENETICS
A significant genetic association was found with SNP rs116799036, 
4-6
The unifying concept of "MHC-I-opathy" has been proposed, suggesting that spondyloarthritis, psoriasis, and BD share clinical findings due to contact points of the body with the external environment (oral mucosa, intestine, skin) or places subject to physical stress, such as entheses, including those of the eyes, vascular walls, and valve regions. It seems that the link between these diseases would be in their associations with MHC class I alleles such as B51, C0602, B27, and ERAP-1.
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Another study has shown that the expression of suppressor of cytokine signaling proteins (SOCS) -as it negatively regulates the cytokine JAK-STAT signaling pathway -affects the production of IFN-gamma, IL-12, IL-23, IL-6 SOCS1, and 3mRNA. These cytokines were greatly increased in the peripheral blood mononuclear cells of BD patients compared to the control group. The authors concluded that SOCS expression was unbalanced in BD patients when compared to controls, and also in patients with systemic involvement when compared to those with mucocutaneous involvement. 
MUCOCUTANEOUS MANIFESTATIONS
Mucocutaneous manifestations are markers of BD and their recognition may allow diagnosis and treatment. 1 The earlier the onset of manifestations, the worse the prognosis, with consequent increase in morbidity and mortality. Genital ulcers, another classic manifestation, are similar to oral ulcers in appearance and course. However, they are less recurrent, have a greater tendency towards scar formation, and some exhibiting necrotic borders. Deeper lesions may complicate the onset of fistulas, especially in females. 9 In men, the most affected site is the scrotum, but affected areas may include the foreskin, penis, glans, and, in some cases, the epididymis (Figures 3 and 4) . In women, ulcers in the vagina and colon can be oligosymptomatic. The most frequently involved region is the major labia ( Figure 5 ).
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Although cutaneous lesions are non-specific for BD, they are essential for diagnosis. Their frequency varies from 48-88% in diagnosed patients. 9 Cutaneous manifestations can be divided into papulopustular lesions, erythema nodosum lesions, thrombophlebitis, and varied cutaneous and vasculitic lesions. Initial lesions exhibit leukocytoclastic vasculitis or neutrophilic aggressions to vessels, while the mature ones are characterized by lymphocytic vasculitis.
Papulopustular lesions are the most prevalent and tend to be more frequent in individuals with positive response to a pathergy test or in those with joint involvement. 4 They usually appear as papules that become pustules in 24-48 hours. 12 These lesions are sterile and may resemble folliculitis or have an acne-like appearance ( Figures 6 and 7) . The latter may be clinically and histopathologically indistinguishable from acne vulgaris. 5 One clue to differentiation is the absence of comedones and marked involvement of the extremities. 11 Poor response to classical therapies against acne, such as antibiotics, is another indicator. 13 Erythema nodosum (EN) lesions occur in one-third of patients, typically affecting the lower limbs. Gluteal regions, the face and neck may also be affected. They do not evolve with ulceration and last between 2-3 weeks. Recurrence is common. 11 It can be dis- Cutaneous ulcers affect up to 3% of patients, are recurrent, and leave scars. They occur in several locations, such as legs, armpits, breasts, and interdigital and inguinal regions ( Figure 9 ). According to some authors, they are the most specific cutaneous manifestation of BD. 16 They are common in affected children. 17 In this age Testing methodology may vary among institutions, but most studies applied a 20-26 G needle to perform 4-6 intradermal punctures at a 45 ° angle in the flexor region of the forearm. This is the site of choice for having a higher positivity rate. 8 The reading
should be performed 48 hours after the procedure. Patients with a disease history of less than 5 years, those with HLA-B51, and cases without treatment tend to have a higher positivity rates. 20 These rates still present an important geographic variation, reaching much higher values in countries alongside the Silk Road, with progressive decline as it moves towards the west. But even in eastern countries, test sensitivity has declined over the decades (from 64.2% in the 1970s to 35.8% in the first decade of this century in an Iranian center). 21 Surgical sterilization of the site and use of disposable needles were suggested as possible justifications for this reduction. 20 However, the cause remains unclear.
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FIgure 11 :
Positive pathergy skin test on dermoscopy: erythematous papule surrounded by an erythematous halo and topped by mild exulcerated crusts (X10 magnification)
FIgure 12 :
Hypopyon: accumulation of pus in the anterior chamber of the eye 
Miscellaneous
Some reports have shown a decrease in the reserve of anti-Müllerian hormone in the ovaries, which has not been confirmed by other publications. 5 Renal impairment is uncommon. In a retrospective study, 16
patients out of 618 were affected. Six had chronic glomerulonephritis, one had tubular acidosis, eight had renal artery stenosis, and one had renal vein thrombosis. 6 The presence of fatigue in inflammatory diseases has been the object of recent research. Its severity and impact on BD are similar to other diseases such as rheumatoid arthritis, systemic lupus erythematosus, and ankylosing spondylitis. It affects both sexes, with no differences between subgroups with different involved organs, and those with active disease are more affected. Depression, anxiety, and physical dysfunction may be associated.
Suicidal thoughts were more frequent among patients with involvement of other organs than those with mucocutaneous forms, signaling the precaution that should be taken in the care of these patients. 6 British reports showed occupational changes, requiring work changes in BD patients, mainly due to speech difficulties caused by oral ulcers. 6 A study performed in Thailand showed increased breast and hematologic cancer among women during the first few years of follow-up.
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DIAGNOSTIC CRITERIA
As there are no pathognomonic laboratory tests, BD diagnosis is based on clinical criteria and on the exclusion of other diseases.
Even so, the diagnosis is challenging considering that the symptoms are not concomitant. Sixteen classification and diagnostic criteria were described. In 2004, an attempt was made to define a set of clinical criteria that could be used to measure BD activity, thus helping to evaluate the treatments. 1 There are numerous attempts to validate indexes that can assess disease activity. Currently, the most commonly used instrument is the Behçet's Disease Current Activity Form. However, the only validated score for measuring specific organ involvement is the Oral Ulcer Composite Index. 23 The multisystemic and episodic character of the disease makes it difficult to assess its activity. Because it has a heterogeneous course that is difficult to evaluate, cutaneous manifestations are common and easy to evaluate. In 2014, Mumcu et al. developed a mucocutaneous activity index that can be used in the management and treatment of BD patients. Although it is a specific score that can help in therapeutic decisions and reduce morbidity, it still lacks validation.
TREATMENT
The main objective of BD patient treatment is to induce and maintain remission and improve quality of life, preventing irreversible damage and exacerbation of mucocutaneous and articular disease. 25, 26 Its main premise is to eliminate inflammation and comprises the use of immunosuppressive agents in severe, life-threatening, and symptomatic manifestations in mucocutaneous and articular diseases. 27 As the clinical expression of the disease is heterogeneous, treatment varies according to severity, organ affected, age at onset, disease duration, and frequency of recurrences. 4 BD treatment is challenging since it is based on fragile studies, mostly consisting of isolated reports or case series, with a few randomized clinical trials.
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ORAL ULCERS
In BD aphthous oral disease, treatment is aimed at pain relief and reduction of inflammation, with decreased recurrences and duration of ulcers. 28 The number of controlled studies is still limited. or refute the use of any of these substances in the systemic treatment of oral ulcers in BS. 28 The conclusions of this review are that there is no gold standard treatment for oral ulcers in BD, and several therapies are used in clinical practice. The heterogeneity of the evaluation methodology and of the results impaired the comparisons, in addition to the frequent lack of a wash-out period for cross over studies. 28 In clinical practice, in addition to advice on oral hygiene, physicians should prescribe the use of antimicrobial mouth rinse (chlorhexidine, tetracycline, triclosan, etc.), silver nitrate, lasers, and topical corticosteroids or pimecrolimus. Patients should also avoid very acidic, salty, or spicy foods. 4 In addition, associated systemic treatment is suggested, starting with colchicine alone or in combination with oral corticosteroids, followed by azathioprine or thalidomide for refractory cases. manifestations. 25 In these circumstances, recommended treatment consists of pulse corticosteroid therapy with methylprednisolone at 1g/daily for three days, followed by prednisone 1mg/kg/daily at slow weaning. 25, 29 For oral or genital ulcers, topical high-potency corticosteroids may be used during the prodromal stage. For larger or more severe ulcers, triamcinolone injections at the base of the ulcer may be attempted. 30 Topical ophthalmic corticosteroids may be used in cases of mild anterior uveitis.
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Non-steroidal anti-inflammatory drugs These drugs are used to treat BD-related arthritis. Indomethacin may be mentioned as an example.
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Colchicine It is the drug most commonly used for mucocutaneous manifestations in BD, supposedly due to its inhibition of neutrophil chemotaxis. 4, 25, 30 Colchicine is effective in the treatment of arthritis and erythema nodosum, and there appears to be a group of patients with oral ulcers who benefit from this treatment, although the results of some randomized clinical trials are disappointing. [25] [26] [27] 29, 32 Side effects reported are mild, such as gastrointestinal and hair loss. 27 Oral ulcers can be treated at the oral dose of 0.6-1mg 2-3 times a day. 27, 30, 32 Mycophenolate mofetil It seems to be an alternative in parenchymal neurologic and pulmonary or ocular BD, but not in cases of mucocutaneous manifestations. However, controlled studies are necessary. 25, 29, 33 Dapsone Dapsone (DDS) inhibits neutrophil chemotaxis and interferes with the production of polymorphonuclear oxygen intermediates, conferring tissue protection from injury by auto-oxidation. 30, 34 Other studies suggest that DDS inhibits leukotriene 4 and neutrophil adhesion to interleukin-stimulated endothelial cells 1. 35 A double-blind, placebo-controlled study verified the efficacy of DDS at a dose of 100 mg/daily in the treatment of mucocutaneous lesions in 20 patients. Patients randomly received either placebo or DDS for three months, and then they crossed over to the alternative treatment. Those who used DDS had oral ulcers with less frequency and duration, fewer cutaneous manifestations (such as erythema nodosum and papulopustular lesions) in addition to low prevalence of positive pathergy test results.
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Cyclosporin A Cyclosporine is mainly indicated for the treatment of ocular impairment in BD. The EULAR, however, recommends that this drug be not used in BD patients with central nervous system involvement, unless an intraocular inflammation is reported, due to the risk of neurotoxicity. 25, 29 Cyclosporin may also be useful in the treatment of acute deep venous thrombosis and in cases of mucocutaneous manifestations, such as oral aphtosis and cutaneous or genital lesions. However, close attention should be paid to its side effects and toxicity. 25, 30 Tacrolimus Tacrolimus has similar efficacy to cyclosporin because of its similarities, but no controlled clinical studies of this drug in BD have been published. Open studies have shown some benefit in cases of ocular involvement.
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Azathioprine
The use of azathioprine in ophthalmic disease is recommended by the EULAR. 26 A randomized controlled clinical study shows its effectiveness in ocular disease control and reduction of a new involvement of the organ. The same study showed decreased development of new genital ulcers, arthritis, and thrombophlebitis, as well as reduced vascular and neurologic impairment in patients treated with azathioprine. 27, 29 Uncontrolled data suggest benefits in the treatment of gastrointestinal and long-term disease in vascular involvement, in addition to neurological, joint and mucocutaneous disease.
27,33
Cyclophosphamide Cyclophosphamide is mainly indicated for parenchymal and large vessel neurological involvement. 25, 27 The EULAR suggests its use in upper vena cava thrombosis or Budd-Chiari syndrome. 25, 26 It is not recommended for ocular disease.
25,29
Thalidomide Although thalidomide is effective in the treatment of orogenital ulcers in BD patients at a dose of 100mg/daily, several studies report that a maintenance dose is required to prevent recurrences. 25, 27, 30, 36 Several studies report its use to treat colitis in BD patients at a dose of 100 to 300mg/daily.
Erythema nodosum lesions worsen during treatment with thalidomide.
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Methotrexate Some studies reported its use in patients with ocular involvement or with neurological diseases.
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Anticoagulants
There is still no scientific evidence of the benefits of anticoagulants in the treatment of deep venous thrombosis and arterial lesions of BD. Therefore, the EULAR does not recommend the use of these drugs with this indication. However, this subject is still controversial. There are numerous case reports of its use in uveoretinitis as monotherapy, usually at a dose of 5mg/kg IV every 6-8 weeks.
Mild side effects have been reported. Although it has a rapid action, repeated infusions are required. 25, 27, 29 There are reports of its use in severe intestinal involvement, without major side effects. It is administered subcutaneously and should not be used in conjunction with azathioprine, at the risk of myelosuppression, or in patients with a history of depression or psychosis, unless there is no other therapy available.
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APREMILAST
It is an inhibitor of phosphodiesterase 4 with oral administration. A double-blind controlled study showed its effectiveness in decreasing oral ulcers in patients with BD 25, 33, 46 Of the 55 patients treated with this drug, one reported reversible bilateral paralysis of the lower limbs, diagnosed as a conversion syndrome, and another reported anal fissure with hemorrhoids after diarrhea.
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OTHER THERAPIES
Reamipid is an amino acid analog of 2(1H)-quinolinone used in the treatment of duodenal ulcers, which acts by reducing oxygen radicals, increasing the production of prostaglandins in the ulcerated mucosa, thus accelerating the healing process. The recommended dose is 100mg three times a day for two months. There are There have been reports of the use of pentoxifylline for oral ulcers, with a better response if associated with colchicine. It is generally used at a dose of 400mg three times a day. 30 Topical anesthetics such as locally applied viscous lidocaine may be used to relieve pain in oral lesions. Topical granulocyte colony stimulating factor can be used for the treatment of mucocutaneous lesions. 25.30 Sucralfate has the function of inducing the proliferation of dermal fibroblasts and the formation of granulation tissue, enhancing the binding of growth factors (which improves healing) and forming a protective barrier by binding to the ulcerated tissue. The dose used is 5 ml four times a day as an oral rinse, or topical application to genital lesions. 30.48 There is a report of the use of topical pimecrolimus associated with oral colchicine showing the same efficacy of the isolated systemic drug, but with greater pain relief in genital lesions. 49 New treatments with alemtuzumab have been investigated for mucocutaneous, ocular, vascular, and neurological diseases. 25.33 Hematopoietic stem cell transplantation has been studied for severe diseases unresponsive to other treatments, as well as azacitidine for oral and intestinal ulcerations, due to its immunomodulatory effect. 
